Cardinal Health's Surging Revenues in 2026
Let's dive into the meat of what Cardinal Health (NYSE: CAH) has cooked up this fiscal year. Revenue in their fourth quarter hit a whopping $63.7 billion, showing a solid 6% bump compared to the same time last year. That's no small potatoes! For the fiscal year 2026, we saw a 14% increase, bringing it to $254.2 billion. Revenues this juicy aren’t something to shrug off.
EPS and Cash Flow: Some Stellar Numbers
The GAAP diluted earnings per share (EPS) for Q4 saw a steep rise of 70%, reaching $1.70. Strip away the fancy one-time IEEPA tariff refund, and the non-GAAP diluted EPS still pulled a 25% increase to $2.60. We're talking about a fiscal year 2026 non-GAAP diluted EPS of $11.26, up 37% — that’s a heck of a climb! What’s more, the operating cash flow for the year sits pretty at $5.2 billion alongside a chunky adjusted free cash flow of $5 billion.
Shares and Market Moves: Not Just a One-Trick Pony
Now, onto those moves with shares. An incremental $350 million share repurchase was completed, adding up to a $1.4 billion buyback for the year, and the board's green light for a staggering $5.0 billion additional repurchase authorization cannot go unnoticed. Seeing such a hefty repurchase plan is like watching a tightrope walker with a net — it's a confidence boost for investors.
Pharmaceutical and Specialty Solutions Segment: A Key Player
Focus on the Pharmaceutical and Specialty Solutions segment — it ramped up by 6% in Q4, with revenue rolling in at $58.8 billion, mainly propelled by ace-boomer pharma sales. Segment profits hitched up 21% to $645 million, driven by the stellar performance of specialty and generic products. The gears are surely turning here!
Global Medical Products and Distribution: An IEEPA Bump
As for the Global Medical Products and Distribution segment, revenue slid a touch, dropping 2% to $3.1 billion, primarily because of the IEEPA tariff refund repayments hitting the books. But check this out, the segment profit, propelled by those refund recognitions, soared to $150 million — talk about finding a silver lining!
What's Ahead: A Risky Yet Promising Outlook
Looking forward, the fiscal year 2027 outlook is assertive, with non-GAAP EPS growth expected between 13% to 15%, targeting $12.40 to $12.60. Cardinal Health's expectations for growth touch all corners, from pharmaceutical revenues climbing another 3% to 5% to a robust $3.5 billion to $4.0 billion in non-GAAP adjusted free cash flow. That’s a roadmap that speaks to ambition.
"Fiscal 2026 was a standout year for Cardinal Health," declares CEO Jason Hollar. In his eyes, double-digit growth across all five segments even before IEEPA boosts highlight the company’s strategic prowess.
Crunching the Competition
There’s no denying that Cardinal Health's game plan is carving a niche in the market. The renewed wholesaler contract with Kroger and the unveil of a new robotic-equipped distribution center in Indianapolis offer a glimpse of their futuristic approach. How this hones their operational capacity is yet to be seen, but they sure are pushing their chips in hard.
Investors, keep your pulse on both the expected acquisition completions, Strive Medical and Diabetes Health, and the looming risks — like DOJ investigations — that could churn the waters.
Steer Wide and Monitor Closely
Concluding this year with a bang, Cardinal Health's financial muscle and bold moves set an intriguing path ahead. This is more than just a hefty earnings report; it’s a signal to take notice. When a company talks about billions like spare change, you better be watching where those dollars land next. But don't let that financial buzz deceive; keep your eye on regulatory risks and macroeconomic hurdles which could steer this ship into rougher seas. Stay nimble, folks!
